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Abstract
Venous thromboembolism, in the form of lower limb deep vein thrombosis and its most dangerous complication 
that is a pulmonary embolism, is a common disease with an increasing incidence associated with the ageing 
population. The scheme of VTE treatment underwent changes when a new drug group — directly and selectively 
acting oral anticoagulants — was introduced. However, the scope of VTE therapy with parenterally administered 
low-molecular-weight heparins was wide, i.e., they produced vast progress in the disease’s treatment in the 1980s.
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Introduction
Venous thromboembolism (VTE) is associated with 
the formation of blood clots inside deep veins, which 
inhibit or block venous blood flow. It includes deep vein 
thrombosis (DVT) and/or pulmonary embolism (PE). 
The most frequent location of DVT are lower limbs; 
it occurs less frequently in the veins of the pelvis and 
upper limbs. The stable thrombi formed damage walls 
of the vein and destroy venous valves, whereas unsta-
ble, balloting thrombi may move and be transported 
to pulmonary vessels with venous blood flow. This 
results in symptoms of pulmonary embolism, which is 
the most frequent cause of sudden death of patients 
treated in hospitals.
Deep vein thrombosis is characterized by limb 
edema and pain, and skin colour may change to bright 
red or blue. Distally located DVT may remain asymp-
tomatic and its only proxymal propagation may result in 
intensified symptoms. Pulmonary embolism frequently 
begins with dyspnea and thoracic pain and it may result 
in hypotonia, loss of conscience, or sudden death.
Annually, it is estimated that DVT and PE are de-
veloped by 57,000 and 36,000 persons, respectively, in 
Poland [1]. The prevalence of DVT is approximately 1 
per 1,000 persons [2], whereas the prevalence of PE 
is from 3 to 4 per 10,000 persons. DVT is present in 
70–80% of persons with PE, but only 15% of PE pa-
tients exhibit clinical symptoms of DVT [3]. A history of 
VTE predisposes a person for its recrudescence. After 
the cessation of anticoagulant therapy, the disease may 
relapse in approx. Ten percent of VTE patients within 
one year from the first event [4], and in 30% of them, 
recrudescence occurs within 10 years from the first 
event [5]. VTE is also associated with considerable 
mortality, which amounts to approx. 5% after 1 year 
of its existence [6].
DVT risk factors can be classified as provoked or 
unprovoked, i.e., those, which cannot be fully identi-
fied [7]. The first group includes surgical procedures, 
prolonged immobilization, injuries, obesity, long travels, 
valvular incompetence, using oral contraceptive agents, 
or hormone replacement therapy and pregnancy [2, 7].
DVT diagnostics includes a physical examination 
and recording of clinical history with concomitant 
use of Wells score [8], additionally a lower limb ultra-
sonography pressure test or full Doppler test should 
be performed [9]. One of the tools used for assessing 
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the risk of VTE in medical treatment ward is the Padua 
Score, where a value ≥ 4 is associated with a high risk 
of developing the disease (2.2–11%) and constitutes 
an indication for commencement of prophylaxis [10]. 
In patients subject to surgical procedures, a modified 
Caprini model for VTE risk assessment can be used [1].
PE diagnostics consists of determining the likeli-
hood of its occurrence using the Wells scale and the 
YEARS index, as well as determining the D-Dimer 
concentration in the blood and possible angioCT test 
of pulmonary arteries. The YEARS score includes three 
parameters: clinical symptoms of VTE, hemoptysis, and 
the assumption that PE is the most likely diagnosis [11].
Prophylactic procedures used in VTE include early 
ambulation of the patient, administration of an anti-
coagulant treatment: low-molecular-weight heparin 
(LMWH), unfractionated heparin (UFH), factor II or Xa 
inhibitors, and mechanical methods such as compres-
sion therapy and intermittent pneumatic compression 
(IPC). In patients with low or moderate risk of bleeding 
who are administered with pharmacological prophylax-
is, concomitant administration of mechanical methods 
of prophylaxis is suggested (stockings with graduated 
compression and/or IPC) whereas in the case of high 
risk of bleeding — use of graduated compression 
stockings and/or IPC at least in the initial period, until 
the risk of bleeding is reduced [12].
VTE treatment guidelines include the possibility of 
using drugs from various groups: LMWH (fondaparinux) 
[13], vitamin K antagonists (VKA) [13], and oral anti-
coagulants that are not vitamin K antagonists (DOAC, 
NOAC) [14]. Thus, it is very important to maintain 
the balance between the prevention of VTE recrudes-
cences and the occurrence of bleeding complications 
in the course of VTE treatment [15]. One of the VKA 
therapy restrictions is the need for constant INR moni-
toring to ensure optimum anticoagulation in numerous 
interactions with other drugs and foods [16]. One of 
the treatment options used in deep vein thrombosis 
therapy and pulmonary embolism is sodium enoxaparin 
administered subcutaneously, two times per day at the 
dose of 100 IU/kg of body weight (1 mg/kg of body 
weight) as well as in a single dose, 150 IU/kg of body 
weight per day (1.5 mg/kg of body weight). The dosage 
decision for a given patient should be individualized, 
based on the experience of the physician and on the 
assessment of thromboembolic and bleeding risk. This 
enoxaparin dosage scheme is indicated in patients with 
a low risk of VTE recrudescence, who do not exhibit 
complications. Enoxaparin dosage at 100 IU/kg of body 
weight (1 mg/kg of body weight) twice per day is ap-
plicable for patients with high recrudescence risk with 
coxal-femoral axis thrombosis, obesity, symptomatic 
pulmonary embolism, and cancer [17].
Enoxaparin is one of the most frequently used and, 
at the same time, clinically studied LMWH, exhibiting 
high anti-Xa activity, low anti-IIa activity, and antithrom-
bin activity, which is mediated by antithrombin III (ATIII). 
Moreover, it inhibits other coagulation factors such as 
VIIa and von Willebrand factor (AWF). Inactivation of 
Xa factor may also occur through the action of LMWH 
on the vessel endothelium and release of endogenous 
tissue factor pathway inhibitor (TFPI) [18].
One of the greatest advantages of LMWH treatment 
is its predictable, dose-dependent antithrombotic 
effect. In the majority of cases, it does not require 
laboratory monitoring. However, in patients with renal 
impairment, LMWH pharmacokinetics is changed, and 
thus it is recommendedto reduce their dose with cre-
atinine clearance < 30 mL/min and possible monitoring 
of the anti-Xa activity level in the body. The authors 
of a meta-analysis conducted in 2006 demonstrated 
an elevated risk of bleeding with therapeutic doses of 
enoxaparin (8.3% vs. 2.4%), at the same time, pointing 
out to a reduction of such complications when utilizing 
empirically determined enoxaparin doses (0.9% vs. 
1.9%) [19]. In all elderly patients, assessment of kidney 
function is recommended prior to the commencement 
of pharmacotherapy [12]. This is of particular impor-
tance in patients with diabetes and chronic renal failure, 
in persons using spironolactones, angiotensin conver-
tase inhibitors because of the high risk of hyperkalemia 
during long-term LMWH use, particularly at therapeutic 
doses occurring as a result of post-heparin inhibition of 
aldosterone secretion by adrenal glands [20].
VTE occurs with high frequency in patients hospital-
ized due to other indications and it is one of the most 
common causes for deaths, which could be prevented 
by applying recommendations of antithrombotic proph-
ylaxis. The risk of its occurrence increases greatly with 
age and in residents < 40 years of age; it ranges from 
25/100,000 to about 300/100,000 per year in residents 
in the age range of 85–89 years [21]. In elderly people, 
the following physiological factors that increase VTE risk 
occur elevated levels of fibrinogen, factors V, VII, VIII, 
IX [22], and von Willebrand factor [23]. At the same 
time, fibrinolytic activity decreases due to increased 
concentration of the inhibitor of plasminogen activator 
type 1(PAI-1) [24].
Advantages of LMWH in comparison to standard 
heparin, which have determined their superiority and 
their gradual replacement of anticoagulant treatment 
were greater bioavailability, longer half-life resulting in 
the possibility of their usage 1–2 times per day and the 
ease of dosage adjustment (based on patient’s body 
weight), lack of the need for monitoring, and lower 
frequency of serious bleeding complications. However, 
it should be borne in mind that the use of enoxaparin 
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in combination with acetylsalicylic acid, NSAID, glu-
cocorticosteroids, clopidogrel, thrombolytic drugs, 
and other antithrombotic drugs impose on physicians 
who recommend such treatments the need for careful 
monitoring of clinical symptoms in patients and periodic 
determination of blood coagulation parameters [17]. 
The oral anticoagulants available in Poland (dabigatran, 
rivaroxaban, and apixaban) do not interact with diet 
components; however, they are not devoid of interac-
tions with other drugs.
A very important issue concerning LMWH selection 
in VTE treatment is the possibility of treatment initia-
tion using LMWH by a family doctor or other general 
practitioners. Only a suspicion of VTE diagnosis con-
stitutes an indication for administration of heparin and 
referring such a patient for further, detailed diagnosis. 
Difficulties in accessing vascular surgery specialists and 
unavailability of quick and detailed diagnostics such as 
Doppler ultrasound examination authorizes physicians 
who are visited by patients with symptoms of edema 
and pain in lower limbs and/or dyspnea, cough, and 
pain in the chest to introduce LMWH treatment and its 
continuation until the diagnosis is confirmed or rejected 
by physicians specializing in the aforementioned fields.
Pregnant and breastfeeding women constitute 
special indications for the use of LMWH as the anti-
coagulant drug for VTE treatment. VTE may occur at 
any stage of gestation or during puerperium. The risk 
of VTE is 5–6-fold higher during gestation [25]. It is 
manifested as PE and/or deep vein thrombosis and on 
average it concerns 1 per 1000 pregnancies [26]. The 
risk factors of VTE in obstetrics can be divided into 
two groups: [1] general, not associated with gestation 
and [2] directly stemming from gestation. This second 
group includes surgical procedures during gestation or 
puerperium, superficial vein thrombosis, cesarian birth, 
polycystic ovary syndrome, prolonged birth, infections 
during pregnancy, premature placental separation and 
immobilization associated with a
high-risk pregnancy. The armamentarium of drugs 
used in VTE prophylaxis includes LMWH, HNF, and 
oral anticoagulants belonging to the vitamin K an-
tagonist group. A prophylactic dose of enoxaparin is 
40 mg every 24 hours, averaged dose is 40 mg every 
12 hours, whereas therapeutic dose, adjusted to the 
body weight is 1mg/1kg of body weight every 12 hours. 
In pregnant women with one event of idiopathic VTE, 
who do not use chronic anticoagulant treatment, the 
following prophylaxis is suggested: Prophylactic dose 
of LMWH, low dose of HNF (5000 IU every 12 hours), 
or administration of vitamin K antagonist as the bridge 
therapy with HNF or LMWH for the minimum period 
of 6 weeks post birth until INR 2.0 is obtained. For 
women with a VTE event and confirmed thrombophilia, 
who do not use anticoagulant therapy the following is 
suggested: Prophylactic or average dose of LMWH, low 
or average dose of HNF, or administration of vitamin K 
antagonist as the bridge therapy with HNF or LMWH 
for the minimum period of 6 weeks post birth until INR 
2.0 is obtained. In women who have had at least two 
VTE events or are using chronic anticoagulant therapy, 
it is suggested that post-birth, LMWH or HNF at an 
adjusted dose is administered and chronic treatment 
with an oral anticoagulant is restored. At the same time, 
in all women who have had DVT, it is suggested to use 
pressure class II elastic stockings. Standard measures for 
the prevention of relapses include administration of oral 
anticoagulants: warfarin and acenocoumarol. Consid-
eration of therapy using LMWH is valid in the situation 
where therapeutic values of the INR index are difficult 
to obtain, VTE relapse occurs during treatment with an 
oral anticoagulant, in pregnant individuals with hepatic 
impairment, in case of alcohol abuse, and in cases which 
are potentially qualified for a surgical procedure. The 
period of therapy application should be individualized 
and it should last for a minimum period of 3 months or it 
should constitute unlimited therapy if it is a subsequent 
VTE event [27]. Administration of vitamin K antagonists 
in the second and third trimester of gestation is asso-
ciated with greater risk for abnormalities within the 
central nervous system and internal organs of the fetus, 
known as fetopathy or warfarin embryopathy [28]. 
Vitale et al. [29] determined that in pregnant women 
with a mechanical heart valve, the prevalence of this 
complication depends on the daily dose of warfarin. It is 
presently believed that the use of vitamin K antagonists 
during gestation exposes the child to an elevated risk 
of malformations, and their use shall be restricted to 
where it is absolutely necessary. Considering the fact 
that vitamin K antagonists do not penetrate milk, their 
usage during breastfeeding is safe [30].
In patients with cancer, the risk of VTE is 4- to 
6-fold greater than in the general population [31]. The 
greatest risk of VTE concerns malignant tumours of the 
pancreas, brain, ovary, stomach, lungs, kidneys, multi-
ple myeloma, non-Hodgkin lymphomas, and Hodgkin 
lymphomas [32]. The risk of VTE is also high during the 
first months of neoplasm diagnosis and it may last for 
many years. Also, the risk of VTE increases several-fold 
during chemotherapy [33]. Antithrombotic drugs used 
in prophylaxis and treatment of VTE patients with can-
cer include LMWH (which are drugs of choice), HNF, 
fondaparinux (in prophylaxis), vitamin K antagonist with 
frequent INR control. (according to current knowledge 
this is no longer current) If previously, a patient has used 
one of the DOAC due to other indications and a VTE 
event occurred, then LMWH is the drug of choice, since 
the incident suggests unsuccessful anticoagulation [34]. 
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Considering certain restrictions of DOAC use in pa-
tients with damaged liver and coagulation disorders, 
with weight in excess of 120 kg, with antiphospholipid 
syndrome, using prasugrel and ticagrelor or drugs in-
teracting with DOAC (influencing glycoprotein P and 
CYP3A4 cytochrome enzymes, antiplatelet agents — 
clopidogrel, ASA, and NSAID), the possibility of LMWH 
therapy should also be taken into account [35].
The use of LMWH is also recommended for patients 
with visceral vein thrombosis associated with cancer 
(20–27% of patients) and in persons with high risk 
of bleeding (cirrhosis, esophagus varices) [36]. Vein 
thrombosis with an atypical location is the cerebral 
vein thrombosis (CVT). It typically occurs in young 
women burdened with risk factors (head traumas, ENT 
and neurosurgical treatments, lumbar punctures, oral 
contraception). During the first days after a diagnosis 
of CVT, LMWH or HNF should be used, followed by 
a possible transition to VKA, if the patient’s condition 
stabilizes [35].
Following the recommendations of the American 
College of Chest Physicians (ACCP), in patients with 
high risk of thromboembolic complications, the recom-
mended procedure is the use of bridge anticoagulation 
therapy in the perioperative period instead of anticoag-
ulant treatment cessation [37]. The REGIMEN register 
comparing the efficiency of bridge therapy of HNF and 
LMWH in a population of 901 patients demonstrated 
that in the group of patients using LMWH, these com-
plications were observed only in 0.9% versus 2.4% 
in the group treated with HNF, while serious bleeding 
occurred in 5.5% versus 3.3% of treated patients, 
respectively [38].
The ACCP guidelines of 2016, which concern VTE 
prophylaxis and treatment [39], recommend that the 
preferred drugs in the first 3 months of treatment of 
patients without cancer are DOAC drugs — apixaban, 
rivaroxaban, edoxaban, and dabigatran. Considering 
the treatment scheme for two of the aforementioned 
drugs, i.e., edoxaban and dabigatran, LMWH can also 
be used for the first 5–10 days of treatment, in the 
preliminary phase.
The minimum period of treatment of the first VTE 
event is 3 months. This time is prolonged in patients 
after the first event of massive, unprovoked, proximal 
DVT or PE with a low or moderate risk of bleeding 
complications [39]. Chronic treatment is also used for 
patients with concomitant cancer and stable relapse risk 
factors. Another indication for relapse is thrombosis 
associated with the presence of a catheter. Perpetual 
antithrombotic treatment should be considered after 
the first event of unprovoked proximal DVT and/or PE 
in the group with a low or moderate risk of bleeding 
complications and following two events of unprovoked 
VTE. One of the possible forms of therapy in the chronic 
treatment of VTE is LMWH used in monotherapy for 
6 months in the course of cancer. It is recommended 
to use the full therapeutic dose for the first month, 
followed by 75% of the therapeutic dose. Another 
indication of chronic treatment is VTE treatment in 
pregnant women [35].
Both in prophylaxis as well as in VTE treatment, 
LMWHs are still widely used despite the introduction 
of DOAC-type drugs in the market. The numerous 
randomization studies on this type of drugs are typically 
non-inferiority tests designed to indicate equal or not 
less efficacy of newly introduced drugs in comparison to 
LMWH, most frequently, enoxaparin. Further research 
is needed to assess the efficacy and safety of their use 
and the time of therapy, which will enable the assess-
ment of individual drugs in small patient groups treated 
for VTE. At present, enoxaparin — most frequently 
used with LMWH, characterized by a large number 
of clinical studies — remains an efficient alternative in 
various clinical aspects of VTE treatment.
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